がん診断の世界市場2021年-2028年:製品別(消耗品、機器)、用途別、エンドユーザー別

◆英語タイトル:Cancer Diagnostics Market by Product (Consumables and Instruments), Application (Breast Cancer, Breast Cancer, Lung Cancer, Blood Cancer, Colorectal Cancer, Skin Cancer, Ovarian Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Cervical Cancer, and Others), and End Use (Hospitals & Clinics, Diagnostic Laboratories, Diagnostic Centers, and Research Institutes): Opportunity Analysis and Industry Forecast, 2021–2028
◆商品コード:AMR21JU065
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2021年5月28日
◆ページ数:239
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD6,168 ⇒換算¥678,480見積依頼/購入/質問フォーム
5 UserUSD6,929 ⇒換算¥762,190見積依頼/購入/質問フォーム
Enterprise UserUSD9,663 ⇒換算¥1,062,930見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査資料では、がん診断の世界市場について調査し、イントロダクション、エグゼクティブサマリー、市場概要、製品別(消耗品、機器)分析、用途別(乳がん、結腸直腸がん、子宮頸がん、肺がん、前立腺がん)分析、エンドユーザー別(病院・クリニック、診断研究所、画像診断センター、研究機関)分析、地域別分析、企業情報などを掲載しています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・がん診断の世界市場規模:製品別(消耗品、機器)
・がん診断の世界市場規模:用途別(乳がん、結腸直腸がん、子宮頸がん、肺がん、前立腺がん)
・がん診断の世界市場規模:エンドユーザー別(病院・クリニック、診断研究所、画像診断センター、研究機関)
・がん診断の世界市場規模:地域別
・企業情報
【レポートの概要】

The cancer diagnostics market was valued at $168,600.04 million in 2020, and is projected to reach $280,590.21 million by 2028, registering a CAGR of 6.9% from 2021 to 2028.

Cancer diagnostics is the process of detecting biomarkers, proteins, and other indicators that contribute to the detection of a cancerous tumor. Effective diagnostic testing is used to confirm or rule out the presence of infection, monitor disease severity, and plan & evaluate clinical outcomes. Diagnostic procedures for cancer may include imaging, laboratory tests (including tests for tumor markers), endoscopic examination, tumor biopsy, surgery, or genetic testing.

The major factor that contributes to the growth of the cancer diagnostics market includes surge in government initiatives and other private organizations to spread awareness regarding early diagnosis and prevention of cancer, which is anticipated to boost the growth of the market in the coming years. Furthermore, the growth in the number of diagnostics laboratories in developed countries is expected to drive the market growth in the next few years. Increase in incidences and prevalence of various types of cancer, such as breast cancer and lung cancer, are expected to drive the growth of the market.

However, huge cost associated with diagnostic imaging system and development of different diagnostic approaches for various cancer mutations may hinder the growth of the market. Conversely, increase in emphasis over health & safety regulations and surge in popularity of yoga and other health related practices will act as a growth opportunity during the forecast period.

The cancer diagnostics market is segmented on the basis of basis of product, application, and end use to provide a detailed assessment of the market. By product, the market is bifurcated into consumables and instruments. Further, consumables are divided into antibodies, kits & reagents, probes, and other consumables. Instruments include pathology-based instruments, imaging instruments, and biopsy instruments. On the basis of application, the market is fragmented into breast cancer, lung cancer, blood cancer, colorectal cancer, skin cancer, ovarian cancer, prostate cancer, kidney cancer, liver cancer, pancreatic cancer, cervical cancer, and others. Based on end use, the market is classified into hospitals & clinics, diagnostic laboratories, diagnostic imaging centers, and research institutes. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2020 to 2028, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of factors that drive and restrain the growth of the market is provided.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS
By Product
• Consumables
o Antibodies
o Kits & Reagents
o Probes
o Other consumables
• Instruments
o Pathology-based Instruments
o Imaging Instruments
o Biopsy Instruments

By Application
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Lung Cancer
• Prostate Cancer
• Skin Cancer
• Blood Cancer
• Kidney Cancer
• Liver Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

By End Use
• Hospitals & Clinics
• Diagnostic Laboratories
• Diagnostic Imaging Centers
• Research Institutes

LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Abbott Laboratories
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Roche Holdings AG (F. Hoffmann-La Roche Ltd.)
• Danaher Corporation (GE Healthcare)
• Hologic, Inc.
• Koninklijke Philips N.V. (Philips Healthcare)
• Qiagen N.V.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific Inc.

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis

3.3.1.Bargaining power of buyers
3.3.2.Bargaining power of suppliers
3.3.3.Thereat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry

3.4.Top player positioning, 2019
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in incidences and prevalence of various cancer types
3.5.1.2.Increase in technological advancements
3.5.1.3.Government initiatives and other organization to spread awareness about cancer
3.5.1.4.Growing number of diagnostics laboratories In developed countries

3.5.2.Restraints

3.5.2.1.Huge cost associated with diagnostic imaging system
3.5.2.2.Risk related with high radiation exposure affecting use of CT scanner

3.5.3.Opportunities

3.5.3.1.Development of diagnostic approaches for various cancer mutation

3.6.Impact Analysis
3.7.Impact Analysis of the Covid-19 on Cancer Diagnostics Market

CHAPTER 4:CANCER DIAGNOSTICS MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Consumables

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market size and forecast, by type
4.2.5.Antibodies

4.2.5.1.Market size and forecast

4.2.6.Kits & Reagents

4.2.6.1.Market size and forecast

4.2.7.Probes

4.2.7.1.Market size and forecast

4.2.8.Other consumables

4.2.8.1.Market size and forecast

4.3.Instruments

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.3.4.Market size and forecast, by type
4.3.5.Pathology-based Instruments

4.3.5.1.Market size and forecast

4.3.6.Imaging Instruments

4.3.6.1.Market size and forecast

4.3.7.Biopsy Instruments

4.3.7.1.Market size and forecast

CHAPTER 5:CANCER DIAGNOSTICS MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Breast Cancer

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Colorectal Cancer

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Cervical Cancer

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Lung Cancer

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Prostate Cancer

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Skin Cancer

5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country

5.8.Blood Cancer

5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country

5.9.Kidney Cancer

5.9.1.Market size and forecast, by region
5.9.2.Market analysis, by country

5.10.Liver Cancer

5.10.1.Market size and forecast, by region
5.10.2.Market analysis, by country

5.11.Pancreatic Cancer

5.11.1.Market size and forecast, by region
5.11.2.Market analysis, by country

5.12.Ovarian Cancer

5.12.1.Market size and forecast, by region
5.12.2.Market analysis, by country

5.13.Others

5.13.1.Market size and forecast, by region
5.13.2.Market analysis, by country

CHAPTER 6:CANCER DIAGNOSTICS MARKET, BY END USE

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospital and Clinics

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Diagnostic Laboratories

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Diagnostic Imaging Centers

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

6.5.Research Institutes

6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country

CHAPTER 7:CANCER DIAGNOSTICS MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. cancer diagnostics market, by product
7.2.2.1.2.U.S. cancer diagnostics market, by application
7.2.2.1.3.U.S. cancer diagnostics market, by end use

7.2.2.2.Canada

7.2.2.2.1.Canada cancer diagnostics market, by product
7.2.2.2.2.Canada cancer diagnostics market, by application
7.2.2.2.3.Canada cancer diagnostics market, by end use

7.2.2.3.Mexico

7.2.2.3.1.Mexico cancer diagnostics market, by product
7.2.2.3.2.Mexico cancer diagnostics market, by application
7.2.2.3.3.Mexico cancer diagnostics market, by end use

7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by end use

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany cancer diagnostics market, by product
7.3.2.1.2.Germany cancer diagnostics market, by application
7.3.2.1.3.Germany cancer diagnostics market, by end use

7.3.2.2.France

7.3.2.2.1.France cancer diagnostics market, by product
7.3.2.2.2.France cancer diagnostics market, by application
7.3.2.2.3.France cancer diagnostics market, by end use

7.3.2.3.UK

7.3.2.3.1.UK cancer diagnostics market, by product
7.3.2.3.2.UK cancer diagnostics market, by application
7.3.2.3.3.UK cancer diagnostics market, by end use

7.3.2.4.Italy

7.3.2.4.1.Italy cancer diagnostics market, by product
7.3.2.4.2.Italy cancer diagnostics market, by application
7.3.2.4.3.Italy cancer diagnostics market, by end use

7.3.2.5.Spain

7.3.2.5.1.Spain cancer diagnostics market, by product
7.3.2.5.2.Spain cancer diagnostics market, by application
7.3.2.5.3.Spain cancer diagnostics market, by end use

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe cancer diagnostics market, by product
7.3.2.6.2.Rest of Europe cancer diagnostics market, by application
7.3.2.6.3.Rest of Europe cancer diagnostics market, by end use

7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by end use

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan cancer diagnostics market, by product
7.4.2.1.2.Japan cancer diagnostics market, by application
7.4.2.1.3.Japan cancer diagnostics market, by end use

7.4.2.2.China

7.4.2.2.1.China cancer diagnostics market, by product
7.4.2.2.2.China cancer diagnostics market, by application
7.4.2.2.3.China cancer diagnostics market, by end use

7.4.2.3.Australia

7.4.2.3.1.Australia cancer diagnostics market, by product
7.4.2.3.2.Australia cancer diagnostics market, by application
7.4.2.3.3.Australia cancer diagnostics market, by end use

7.4.2.4.India

7.4.2.4.1.India cancer diagnostics market, by product
7.4.2.4.2.India cancer diagnostics market, by application
7.4.2.4.3.India cancer diagnostics market, by end use

7.4.2.5.South Korea

7.4.2.5.1.South Korea cancer diagnostics market, by product
7.4.2.5.2.South Korea cancer diagnostics market, by application
7.4.2.5.3.South Korea cancer diagnostics market, by end use

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific cancer diagnostics market, by product
7.4.2.6.2.Rest of Asia-Pacific cancer diagnostics market, by application
7.4.2.6.3.Rest of Asia-Pacific cancer diagnostics market, by end use

7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by end use

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil cancer diagnostics market, by product
7.5.2.1.2.Brazil cancer diagnostics market, by application
7.5.2.1.3.Brazil cancer diagnostics market, by end use

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia cancer diagnostics market, by product
7.5.2.2.2.Saudi Arabia cancer diagnostics market, by application
7.5.2.2.3.Saudi Arabia cancer diagnostics market, by end use

7.5.2.3.South Africa

7.5.2.3.1.South Africa cancer diagnostics market, by product
7.5.2.3.2.South Africa cancer diagnostics market, by application
7.5.2.3.3.South Africa cancer diagnostics market, by end use

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA cancer diagnostics market, by product
7.5.2.4.2.Rest of LAMEA cancer diagnostics market, by application
7.5.2.4.3.Rest of LAMEA cancer diagnostics market, by end use

7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by end use

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.BECTON, DICKINSON AND COMPANY

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.Bio-Rad Laboratories, Inc.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.Roche Holdings AG (F. Hoffmann-La Roche Ltd.)

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.Danaher Corporation (GE Healthcare)

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.Hologic, Inc.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.KONINKLIJKE PHILIPS N.V. (Philips Healthcare)

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.Qiagen N.V.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.Siemens Healthcare GmbH

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.Thermo Fisher Scientific

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
TABLE 02.CONSUMABLES CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 03.CONSUMABLES CANCER DIAGNOSTICS MARKET, BY TYPE, 2020-2028, ($MILLION)
TABLE 04.INSTRUMENTS CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 05.INSTRUMENTS CANCER DIAGNOSTICS MARKET, BY TYPE, 2020-2028, ($MILLION)
TABLE 06.GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 07.BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 08.COLORECTAL CANCER, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 09.CERVICAL CANCER, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 10.LUNG CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 11.PROSTSATE CANCER, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 12.SKIN CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 13.BLOOD CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 14.KIDNEY CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 15.LIVER CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 16.PANCREATIC CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 17.OVARIAN CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 18.OTHERS CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 19.GLOBAL CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028 ($MILLION)
TABLE 20.HOSPITALS AND CLINICS, CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 21.DIAGNOSTICS LABORATORIES CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 22.DIAGNOSTICS IMAGING CENTERS CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 23.RESEARCH INSTITUTES CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 24.CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 25.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 26.U.S. CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 27.U.S. CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 28.U.S. CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 29.CANADA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 30.CANADA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 31.CANADA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 32.MEXICO CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 33.MEXICO CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 34.MEXICO CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 35.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 36.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 37.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 38.EUROPE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 39.GERMANY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 40.GERMANY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 41.GERMANY CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 42.FRANCE CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 43.FRANCE CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 44.FRANCE CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 45.UK CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 46.UK CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 47.UK CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 48.ITALY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 49.ITALY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 50.ITALY CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 51.SPAIN CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 52.SPAIN CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 53.SPAIN CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 54.REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 55.REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 56.REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 57.EUROPE CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 58.EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 59.EUROPE CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 60.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 61.JAPAN CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 62.JAPAN CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 63.JAPAN CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 64.CHINA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 65.CHINA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 66.CHINA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 67.AUSTRALIA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 68.AUSTRALIA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 69.AUSTRALIA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 70.INDIA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 71.INDIA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 72.INDIA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 73.SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 74.SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 75.SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 76.REST OF ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 77.REST OF ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 78.REST OF ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 79.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 80.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 81.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 82.LAMEA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 83.LAMEA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 (UNITS)
TABLE 84.BRAZIL CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 85.BRAZIL CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 86.BRAZIL CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 87.SAUDI ARABIA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 88.SAUDI ARABIA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 89.SAUDI ARABIA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 90.SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 91.SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 92.SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 93.REST OF LAMEA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 94.REST OF LAMEA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 95.REST OF LAMEA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 96.LAMEA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 97.LAMEA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 98.LAMEA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 99.ABBOTT: COMPANY SNAPSHOT
TABLE 100.ABBOTT: OPERATING SEGMENT
TABLE 101.ABBOTT LABORATORIES PLC: PRODUCT PORTFOLIO
TABLE 102.BD: SNAPSHOT
TABLE 103.BD: OPERATING SEGMENTS
TABLE 104.BD: PRODUCT PORTFOLIO
TABLE 105.BD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106.BIO-RAD: COMPANY SNAPSHOT
TABLE 107.MYRIAD: OERATING SEGMENT
TABLE 108.BIO-RAD: PRODUCT PORTFOLIO
TABLE 109.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 110.ROCHE: COMPANY SNAPSHOT
TABLE 111.ROCHE: OPERATING SEGMENTS
TABLE 112.ROCHE: PRODUCT PORTFOLIO
TABLE 113.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.DANAHER: COMPANY SNAPSHOT
TABLE 115.DANAHER: OPERATING SEGMENT
TABLE 116.DANAHER: PRODUCT PORTFOLIO
TABLE 117.DANAHER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118.HOLOGIC: COMPANY SNAPSHOT
TABLE 119.HOLOGIC: OERATING SEGMENT
TABLE 120.HOLOGIC: PRODUCT PORTFOLIO
TABLE 121.HOLOGIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122.PHILIPS: COMPANY SNAPSHOT
TABLE 123.PHILIPS: OERATING SEGMENT
TABLE 124.PHILIPS: PRODUCT PORTFOLIO
TABLE 125.PHILIPS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 126.QIAGEN: COMPANY SNAPSHOT
TABLE 127.QIAGEN: PRODUCT PORTFOLIO
TABLE 128.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 129.SIEMENS: COMPANY SNAPSHOT
TABLE 130.SIEMENS: OERATING SEGMENTS
TABLE 131.SIEMENS: PRODUCT PORTFOLIO
TABLE 132.SIEMENS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 133.THERMO: COMPANY SNAPSHOT
TABLE 134.THERMO: OPERATING SEGMENTS
TABLE 135.THERMO: PRODUCT PORTFOLIO
TABLE 136.THERMO: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.GLOBAL CANCER DIAGNOSTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2019
FIGURE 12.PIE CHART FOR CANCER CASES DIAGNOSED IN 2020
FIGURE 13.COMPARATIVE ANALYSIS OF CONSUMABLES CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 14.ANTIBODIES MARKET, 2020-2028, ($MILLION)
FIGURE 15.KITS & REAGENTS MARKET, 2020-2028, ($MILLION)
FIGURE 16.KITS & REAGENTS MARKET, 2020-2028, ($MILLION)
FIGURE 17.KITS & REAGENTS MARKET, 2020-2028, ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF INSTRUMENTS CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 19.PATHOLOGY-BASED INSTRUMENTS MARKET, 2020-2028, ($MILLION)
FIGURE 20.IMAGING INSTRUMENTS MARKET, 2020-2028, ($MILLION)
FIGURE 21.BIOPSY INSTRUMENTS MARKET, 2020-2028, ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF COLORECTAL CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF CERVICAL CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF LUNG CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF PROSTATE CANCER, CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF SKIN CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 28.COMPARATIVE ANALYSIS OF BLOOD CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF KIDNEY CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 30.COMPARATIVE ANALYSIS OF LIVER CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 31.COMPARATIVE ANALYSIS OF PANCREATIC CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 32.COMPARATIVE ANALYSIS OF OVARIAN CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 33.COMPARATIVE ANALYSIS OF OTHERS CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 34.COMPARATIVE ANALYSIS OF RETAIL PHARMACIES CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 35.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 36.COMPARATIVE ANALYSIS OF E-COMMERCE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 37.COMPARATIVE ANALYSIS OF E-COMMERCE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 38.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 41.BD: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.BD: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 44.BIO-RAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 45.BIO-RAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 46.BIO-RAD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 47.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 48.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 ($MILLION)
FIGURE 49.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 50.DANAHER: REVENUE SHARE BY SEGMENT, 2020
FIGURE 51.DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 52.HOLOGIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 53.HOLOGIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 54.HOLOGIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 55.PHILIPS: NET SALES, 2018–2020 ($MILLION)
FIGURE 56.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 57.PHILIPS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 58.QIAGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 59.QIAGEN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 60.SIEMENS: NET SALES, 2018-2020 ($MILLION)
FIGURE 61.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 62.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 63.THERMO: NET SALES, 2018–2020 ($MILLION)
FIGURE 64.THERMO: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 65.THERMO: REVENUE SHARE, BY REGION, 2020 (%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[がん診断の世界市場2021年-2028年:製品別(消耗品、機器)、用途別、エンドユーザー別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆